| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8793888 | Ophthalmology | 2018 | 9 Pages |
Abstract
New MA was detected in 29% of study eyes after 24 months of treatment. Clinically significant BCVA gains were achieved with MA present over 24 months. Baseline subretinal fluid absence, intraretinal cyst presence, and fellow eye atrophy presence were associated with month 24 MA presence. With existing data, the benefits of ranibizumab for neovascular AMD outweighed the risk of MA development over 24 months in HARBOR, although outcomes >2 years were not evaluated.
Keywords
ETDRSMinimally Classic/Occult Trial of the Anti-VEGF Antibody Ranibizumab In the Treatment of Neovascular AMDIVANVEGF Trap-Eye: Investigation of Efficacy and Safety in Wet AMDCATTBCVAPEDPRNRPECNVAMDCFPChoroidal neovascularizationMacular atrophyfluorescein angiographyretinal pigment epitheliumbest-corrected visual acuityPigment epithelial detachmentearly treatment diabetic retinopathy studyage-related macular degenerationpro re nataconfidence intervalVascular endothelial growth factorVascular Endothelial Growth Factor (VEGF)AnchorMarinaComparison of Age-Related Macular Degeneration Treatments Trialshazard ratioView
Related Topics
Health Sciences
Medicine and Dentistry
Ophthalmology
Authors
SriniVas R. MD, Lisa L. PharmD, Beiying PhD, Anne E. MD, J. Jill MD,